MCID: DBT032
MIFTS: 22

Diabetes Mellitus, Insulin-Dependent, 22

Categories: Genetic diseases, Metabolic diseases, Rare diseases, Endocrine diseases

Aliases & Classifications for Diabetes Mellitus, Insulin-Dependent, 22

MalaCards integrated aliases for Diabetes Mellitus, Insulin-Dependent, 22:

Name: Diabetes Mellitus, Insulin-Dependent, 22 54 71 29 13 69
Iddm22 12 71
Insulin-Dependent Diabetes Mellitus 22 12
Type 1 Diabetes Mellitus 22 12

Classifications:



External Ids:

OMIM 54 612522
Disease Ontology 12 DOID:0110759
ICD10 33 E10
MedGen 40 C2675864
MeSH 42 D003922

Summaries for Diabetes Mellitus, Insulin-Dependent, 22

UniProtKB/Swiss-Prot : 71 Diabetes mellitus, insulin-dependent, 22: A multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical features are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.

MalaCards based summary : Diabetes Mellitus, Insulin-Dependent, 22, is also known as iddm22. An important gene associated with Diabetes Mellitus, Insulin-Dependent, 22 is CCR5 (C-C Motif Chemokine Receptor 5 (Gene/Pseudogene)). The drugs rituximab and Pancrelipase have been mentioned in the context of this disorder. Affiliated tissues include testes, pancreas and kidney.

Disease Ontology : 12 A type 1 diabetes mellitus that has material basis in mutation of the CCR5 gene on chromosome 3p21.31.

Description from OMIM: 612522

Symptoms & Phenotypes for Diabetes Mellitus, Insulin-Dependent, 22

Clinical features from OMIM:

612522

Drugs & Therapeutics for Diabetes Mellitus, Insulin-Dependent, 22

Drugs for Diabetes Mellitus, Insulin-Dependent, 22 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 43)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
rituximab Approved Phase 4 174722-31-7 10201696
2
Pancrelipase Approved Phase 4,Phase 2,Phase 1,Early Phase 1 53608-75-6
3 Antibodies Phase 4
4 Antibodies, Monoclonal Phase 4
5 Antirheumatic Agents Phase 4
6 Autoantibodies Phase 4
7 Immunoglobulins Phase 4
8 Gastrointestinal Agents Phase 4,Phase 2,Phase 1,Early Phase 1
9 glucagon Phase 4,Phase 3,Phase 2,Phase 1
10 Glucagon-Like Peptide 1 Phase 4,Phase 3,Phase 2,Phase 1
11 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
12 Hormones Phase 4,Phase 3,Phase 2,Phase 1
13 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
14 Incretins Phase 4,Phase 3,Phase 2,Phase 1
15 insulin Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
16 Insulin, Globin Zinc Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
17 pancreatin Phase 4,Phase 2,Phase 1,Early Phase 1
18 Pharmaceutical Solutions Phase 4,Phase 2,Phase 1
19
Insulin Glargine Approved Phase 3,Phase 1 160337-95-1
20
Zinc Approved Phase 3,Phase 2,Phase 1 7440-66-6 32051 23994
21
Insulin Aspart Approved Phase 3,Phase 2 116094-23-6 16132418
22
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754 657311
23
Liraglutide Approved Phase 3,Phase 1 204656-20-2 44147092
24
Insulin Detemir Approved Phase 3 169148-63-4 5311023
25 Hypoglycemic Agents Phase 3,Phase 2,Phase 1,Early Phase 1
26 Biphasic Insulins Phase 3
27 Insulin degludec, insulin aspart drug combination Phase 3
28 Insulin, Long-Acting Phase 3
29 Cortisol succinate Phase 3
30 Hydrocortisone 17-butyrate 21-propionate Phase 3
31 Hydrocortisone acetate Phase 3
32 Insulin, Isophane Phase 3
33 Isophane insulin, beef Phase 3
34 Isophane Insulin, Human Phase 3
35 Protamines Phase 3
36
Insulin Lispro Approved Phase 2 133107-64-9
37
Exenatide Approved, Investigational Phase 1 141758-74-9 15991534
38
Pramlintide Approved, Investigational Phase 1 151126-32-8
39 Tomato Approved, Nutraceutical
40 Liver Extracts
41 gastric inhibitory polypeptide
42 tyrosine Nutraceutical
43 Tea Nutraceutical

Interventional clinical trials:

(show all 40)

id Name Status NCT ID Phase Drugs
1 Immune Intervention With Rituximab to Preserve Beta Cell Function in Early Onset Type 1 Diabetes Unknown status NCT01280682 Phase 4 rituximab
2 Treatment of Low Blood Sugar With Glucagon Among Patients With Type 1 Diabetes Unknown status NCT02232971 Phase 4 Glucagon
3 Improving Blood Pressure Management in Patients With Diabetes Completed NCT00374270 Phase 4
4 Immunogenicity Safety Study of Wockhardt's Recombinant Insulin Analogue in Type 1 Diabetic Patients Unknown status NCT01352663 Phase 3
5 A Comparison of Pharmacodynamics and Pharmacokinetics of Insulin Aspart, BIAsp70, BIAsp50 and Fast-acting Human Insulin Completed NCT00888732 Phase 3 Insulin Aspart, BIAsp 70, BIAsp50, Human Insulin
6 Comparison of Lantus and Neutral Protamine Hagedorn (NPH) Insulin in the Dawn Phenomenon Completed NCT00694122 Phase 3 Lantus (glargine)
7 The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes Completed NCT02098395 Phase 3 liraglutide;liraglutide;liraglutide;placebo;placebo;placebo
8 Safety of Insulin Detemir for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes Mellitus Completed NCT01709929 Phase 3 insulin detemir
9 Comparison of NN1250 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes Completed NCT01074268 Phase 3 insulin degludec;insulin detemir;insulin aspart
10 Comparison of an Artificial Pancreas Versus Threshold Low Glucose Suspend in Type 1 Diabetic Children Unknown status NCT02509429 Phase 2
11 Pilot Study Investigating the Feasibility of Determining the Endogenous Glucose Production During a Hypoglycaemia Completed NCT02028078 Phase 2 Insulin human
12 Closed-loop Control of Overnight Glucose Levels (Artificial Pancreas) in Children With Type 1 Diabetes in a Diabetes Camp Completed NCT02189694 Phase 2
13 An Open Label, Pilot Investigation, to Assess the Safety and Efficacy of Transplantation of Macro-encapsulated Human Islets Within the Bioartificial Pancreas Beta-Air in Patients With Type 1 Diabetes Mellitus Active, not recruiting NCT02064309 Phase 1, Phase 2
14 Safety and Efficacy of Arterial Delivery of Autologous Bone Marrow Cells in the Treatment of Insulin-Dependent Diabetes Withdrawn NCT00971503 Phase 2
15 Closed Loop System With Pramlintide Versus Exenatide Completed NCT01269008 Phase 1
16 The Effect of Liraglutide Adjunct to Insulin on Glucagon Response to Hypoglycaemia in Subjects With Type 1 Diabetes Completed NCT01536665 Phase 1 liraglutide;placebo
17 Trial to Compare the Relative Pharmacodynamic Properties of Different Glucagon Dosages Completed NCT01916265 Phase 1 Glucagon
18 A Study of LY2605541 Versus Insulin Glargine on Blood Sugar Completed NCT01654380 Phase 1 LY2605541
19 Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes Recruiting NCT02745808 Phase 1
20 Study of PTPN22 C1858T Polymorphism in Children and Adolescents of Greek Origin With T1DM Completed NCT01276743
21 Impact of c242T Polymorphism of p22phox in Diabetic type1 Nephropathy Completed NCT01371955
22 Effects of Low Intensity Aerobic Exercise on the Microvascular Endothelial Function of Patients With Type 1 Diabetes Completed NCT02441504
23 Outpatient Control-to-Range: System and Monitoring Testing Completed NCT01697150
24 Real-Time Continuous Glucose Monitoring (RT-CGM) in Patients With Type 1 Diabetes at High Risk for Low Glucose Values Using Multiple Daily Injections (MDI) in Germany (HYPODE-STUDY) Completed NCT02671968
25 Controlled Insulin Delivery: Combining Technology With Treatment Completed NCT01484457 Early Phase 1
26 Severe Hypoglycemia in Pregnant Women With Type 1 Diabetes Completed NCT00435565
27 Feasibility Study of a Portable Artificial Pancreas System in Type 1 Diabetes Mellitus (T1DM) - Padova Completed NCT01447992 Early Phase 1
28 Feasibility Study of a Portable Artificial Pancreas System in Type 1 Diabetes Mellitus (T1DM) - Montpellier Completed NCT01447979 Early Phase 1
29 Safety Study of Repeated Doses of Glucagon on Animal Starch in the Liver Completed NCT01986231 Glucagon
30 Early Feasibility Study 2 of Outpatient Control-to-Range - Testing System Efficacy (Italy) Completed NCT01727817
31 Early Feasibility Study 2 of Outpatient Control-to-Range - Testing System Efficacy (France) Completed NCT01742741
32 Early Feasibility Study 2 of Outpatient Control-to-Range - Testing System Efficacy Completed NCT01714505
33 Hybrid Closed Loop Insulin Delivery System in Hypoglycemia Recruiting NCT03215914
34 Home Testing of Day and Night Closed Loop With Pump Suspend Feature Recruiting NCT02523131
35 Randomized Crossover Study to Test the Impact of Using a Software for Smartphones and Tablets in Treating Type 1 Diabetes Recruiting NCT02107326
36 T1D Risk Assessment in Kids With Relatives Recruiting NCT02184676
37 PRECISION Study: Evaluating the Accuracy of the LabPatch Continuous Glucose Monitor Recruiting NCT03262415
38 Mixed Meal Test in Type 1 Diabetes on Insulin Pump Therapy: Optimization of Artificial Pancreas Active, not recruiting NCT02003274
39 Comparison of Two Protocols on the Implementation of a Fasting Day in Type 1 Diabetes Active, not recruiting NCT02667769
40 DiabetesFlex - Patient Involvement and Patient-reported Outcome Measures in Type 1 Diabetes Not yet recruiting NCT03202732

Search NIH Clinical Center for Diabetes Mellitus, Insulin-Dependent, 22

Genetic Tests for Diabetes Mellitus, Insulin-Dependent, 22

Genetic tests related to Diabetes Mellitus, Insulin-Dependent, 22:

id Genetic test Affiliating Genes
1 Diabetes Mellitus, Insulin-Dependent, 22 29

Anatomical Context for Diabetes Mellitus, Insulin-Dependent, 22

MalaCards organs/tissues related to Diabetes Mellitus, Insulin-Dependent, 22:

39
Testes, Pancreas, Kidney, Eye, Liver, Endothelial, Bone

Publications for Diabetes Mellitus, Insulin-Dependent, 22

Variations for Diabetes Mellitus, Insulin-Dependent, 22

Expression for Diabetes Mellitus, Insulin-Dependent, 22

Search GEO for disease gene expression data for Diabetes Mellitus, Insulin-Dependent, 22.

Pathways for Diabetes Mellitus, Insulin-Dependent, 22

GO Terms for Diabetes Mellitus, Insulin-Dependent, 22

Sources for Diabetes Mellitus, Insulin-Dependent, 22

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....